Measuring HER2-Receptor Expression In Metastatic Breast Cancer Using [<sup>68</sup>Ga]ABY-025 Affibody PET/CT
Jens Nørkær Sørensen(Technical University of Denmark), Henrik Lindman(Uppsala University), Joachim Feldwisch(Uppsala University), Anders Wennborg(Affibody (Sweden)), Irina Velikyan(Uppsala University), Mark Lubberink(Uppsala University), Dan Sandberg(Uppsala University), Vladimir Tolmachev(Uppsala University), Jörgen Carlsson(Uppsala University Hospital), Anna Orlova(Uppsala University), Helena Olofsson, Mattias Sandström(Uppsala University Hospital)
Cited by 269
Related Papers
Cardiovascular Effects of Treatment With the Ketone Body 3-Hydroxybutyrate in Chronic Heart Failure Patients
|Circulation|2019|513
Breast Cancer in Young Women: Poor Survival Despite Intensive Treatment
|PLoS ONE|2009|504
Tailored fluorouracil, epirubicin, and cyclophosphamide compared with marrow-supported high-dose chemotherapy as adjuvant treatment for high-risk breast cancer: a randomised trial
|The Lancet|2000|343
Quantitative Assessment of Myocardial Perfusion in the Detection of Significant Coronary Artery Disease
|Journal of the American College of Cardiology|2014|324
Prospective of <sup>68</sup>Ga-Radiopharmaceutical Development
|Theranostics|2014|306